Bellevue Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $20.3M | Sell |
93,567
-41,292
| -31% | -$9.16M | 0.48% | 50 |
|
|
2025
Q4 | $30.8M | Sell |
134,859
-36,011
| -21% | -$8.2M | 0.58% | 38 |
|
|
2025
Q3 | $39.6M | Buy |
170,870
+11,209
| +7% | +$2.28M | 0.82% | 31 |
|
|
2025
Q2 | $29.6M | Buy |
159,661
+24,421
| +18% | +$4.54M | 0.65% | 39 |
|
|
2025
Q1 | $28.3M | Buy |
135,240
+89,981
| +199% | +$17.5M | 0.63% | 37 |
|
|
2024
Q4 | $8.04M | Buy |
45,259
+2,373
| +6% | +$436K | 0.15% | 84 |
|
|
2024
Q3 | $8.47M | Buy |
42,886
+682
| +2% | +$127K | 0.14% | 89 |
|
|
2024
Q2 | $7.24M | Buy |
42,204
+14,611
| +53% | +$2.42M | 0.12% | 92 |
|
|
2024
Q1 | $5.02M | Buy |
27,593
+20,866
| +310% | +$3.6M | 0.08% | 97 |
|
|
2023
Q4 | $1.04M | Buy |
6,727
+1,964
| +41% | +$286K | 0.02% | 119 |
|
|
2023
Q3 | $710K | Sell |
4,763
-1,411
| -23% | -$207K | 0.01% | 138 |
|
|
2023
Q2 | $832K | Sell |
6,174
-11,002
| -64% | -$1.61M | 0.01% | 133 |
|
|
2023
Q1 | $2.74M | Buy |
17,176
+976
| +6% | +$149K | 0.04% | 112 |
|
|
2022
Q4 | $2.62M | Sell |
16,200
-797
| -5% | -$122K | 0.03% | 121 |
|
|
2022
Q3 | $2.28M | Buy |
16,997
+16,189
| +2,004% | +$2.32M | 0.03% | 121 |
|
|
2022
Q2 | $124K | Sell |
808
-310,692
| -100% | -$47.5M | ﹤0.01% | 158 |
|
|
2022
Q1 | $50.5M | Buy |
311,500
+4,600
| +1% | +$668K | 0.59% | 56 |
|
|
2021
Q4 | $41.6M | Buy |
306,900
+24,000
| +8% | +$2.84M | 0.43% | 72 |
|
|
2021
Q3 | $30.5M | Sell |
282,900
-41,300
| -13% | -$4.72M | 0.31% | 89 |
|
|
2021
Q2 | $36.5M | Sell |
324,200
-59,900
| -16% | -$6.75M | 0.36% | 86 |
|
|
2021
Q1 | $41.6M | Buy |
384,100
+8,600
| +2% | +$920K | 0.44% | 73 |
|
|
2020
Q4 | $40.2M | Buy |
375,500
+338,500
| +915% | +$32.5M | 0.46% | 62 |
|
|
2020
Q3 | $3.24M | Hold |
37,000
| – | – | 0.04% | 134 |
|
|
2020
Q2 | $3.63M | Buy |
37,000
+11,600
| +46% | +$1.02M | 0.05% | 126 |
|
|
2020
Q1 | $1.94M | Sell |
25,400
-17,100
| -40% | -$1.46M | 0.04% | 131 |
|
|
2019
Q4 | $3.76M | Buy |
+42,500
| New | +$3.53M | 0.06% | 116 |
|
|
2018
Q1 | – | Sell |
-19,500
| Closed | -$1.89M | – | 125 |
|
|
2017
Q4 | $1.89M | Sell |
19,500
-83,277
| -81% | -$7.85M | 0.2% | 82 |
|
|
2017
Q3 | $9.13M | Sell |
102,777
-11,797
| -10% | -$898K | 0.96% | 35 |
|
|
2017
Q2 | $8.31M | Buy |
114,574
+11,873
| +12% | +$798K | 0.98% | 41 |
|
|
2017
Q1 | $6.69M | Buy |
102,701
+87,701
| +585% | +$5.51M | 0.89% | 42 |
|
|
2016
Q4 | $939K | Hold |
15,000
| – | – | 0.19% | 87 |
|
|
2016
Q3 | $946K | Hold |
15,000
| – | – | 0.17% | 96 |
|
|
2016
Q2 | $929K | Hold |
15,000
| – | – | 0.17% | 99 |
|
|
2016
Q1 | $857K | Buy |
+15,000
| New | +$836K | 0.16% | 98 |
|
Other funds holding ABBV
VCM
VPM
Bellevue Group's ABBV Position: Q1 2026 in Review
Bellevue Group reduced its AbbVie (ABBV) stake by 31% in Q1 2026, selling an estimated $9.16M and leaving 93,567 shares worth $20.3M. The position accounts for 0.48% of the portfolio, ranked #50.
Bellevue Group first reported a position in ABBV in Q1 2016 and has held it in 34 quarters since. The position peaked at $50.5M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Bellevue Group held 93,567 shares of AbbVie worth $20.3M as of Q1 2026.
- Bellevue Group sold 41,292 AbbVie shares in Q1 2026, an estimated $9.16M.
- AbbVie made up 0.48% of Bellevue Group's portfolio in Q1 2026, its #50 holding.
- Bellevue Group first reported a position in AbbVie in Q1 2016 and has held it in 34 quarters since.
- Bellevue Group's AbbVie position peaked at $50.5M in Q1 2022.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.